Cytokinetics INC Form 4 insider transactions

Cytokinetics Director Wendell Wierenga acquired 99 shares of common stock at $62.80 per share as part of an equity compensation program.

Cytokinetics President and CEO Robert I. Blum sold 5,000 shares of common stock on October 16, 2025, under a Rule 10b5-1 trading plan.

Cytokinetics director Robert Arthur Harrington acquired 199 shares of common stock at $62.80 as part of an equity compensation program.

Cytokinetics Director John T. Henderson acquired 338 shares of common stock at $62.80 per share as part of an equity in lieu of cash retainer program.

Cytokinetics Director Edward M. Kaye MD acquired 199 shares of common stock at $62.80 per share as part of an equity retainer program.

Cytokinetics Director Nancy Wysenski acquired 99 shares of common stock at $62.80 per share as part of an equity in lieu of cash retainer program, increasing her total beneficial ownership to 30,873 shares.

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, exercised options and sold 2,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Cytokinetics Director Edward M. Kaye MD sold 6,757 shares of common stock at $60 per share, reducing his direct beneficial ownership to 9,778 shares, pursuant to a Rule 10b5-1 plan.

Cytokinetics President & CEO Robert I Blum sold 5,000 shares of common stock at $55.05 per share under a pre-arranged trading plan.

A director at Cytokinetics Inc. has filed a Form 4 indicating a future sale of 6,695 common shares on September 30, 2025, under a Rule 10b5-1 plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and subsequently sold an equivalent number of common shares.

Cytokinetics President & CEO Robert I. Blum sold 5,000 shares of common stock for $49.77 per share under a pre-arranged 10b5-1 trading plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and sold an equal number of shares on September 9, 2025, under a pre-arranged 10b5-1 plan.

Cytokinetics Director Edward M. Kaye sold 6,756 shares of common stock for $50 per share on September 2, 2025, as part of a pre-arranged trading plan.

A director at Cytokinetics Inc. reported a future sale of 2,150 common shares at $48.67 per share under a pre-arranged trading plan.

Cytokinetics President and CEO, Robert I. Blum, sold 5,000 shares of common stock for $48.76 per share under a pre-arranged 10b5-1 trading plan.

Cytokinetics Director James M. Daly was granted 27,450 non-qualified stock options with an exercise price of $37.84, effective August 19, 2025.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, sold 2,000 shares of common stock for $38.31 per share after exercising stock options at $10.60 per share.

Cytokinetics CEO Robert I. Blum sold 5,000 shares of common stock for $38.42 per share in a pre-planned transaction.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and simultaneously sold shares on August 5, 2025.

Cytokinetics President and CEO Robert I. Blum sold 5,000 shares of common stock for $36.45 per share in a transaction executed under a Rule 10b5-1 trading plan.

A Cytokinetics executive exercised stock options and simultaneously sold an equivalent number of shares as part of a pre-arranged trading plan.

Cytokinetics Inc. Director John T. Henderson acquired 559 shares of common stock at $38.01 per share as part of an equity in lieu of cash retainer program.

Cytokinetics Director Nancy Wysenski acquired 164 shares of common stock at $38.01 per share on July 15, 2025, as part of a director equity in lieu of cash retainer program.

Cytokinetics Inc. Director Wendall Wierenga acquired 164 shares of common stock at $38.01 per share as part of a director equity program, increasing total beneficial ownership to 32,345 shares.

Cytokinetics Director Edward M. Kaye, MD, acquired 328 shares of common stock at $38.01 per share as part of the director equity program.

Cytokinetics Director Robert Arthur Harrington acquired 328 shares of common stock as part of the company's director equity in lieu of cash retainer program.

Cytokinetics President and CEO Robert Blum has filed a Form 4 indicating a future sale of 5,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

A Cytokinetics executive, Fady Ibraham Malik, exercised stock options and subsequently sold 2,000 shares of common stock for a profit, as disclosed in a recent SEC Form 4 filing.

Cytokinetics Inc.'s President and CEO, Robert I. Blum, sold 5,000 shares of common stock for $33.55 per share on July 1, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.